NEWTON, Mass./EWORLDWIRE/Aug. 21, 2009 --- NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the formation of a Medical Advisory Board (MAB) to assist the company in the clinical development of NH02D, its novel mechanism of action, drug candidate for the treatment of premature ejaculation (PE).Members of the company's MAB include the following clinicians and scientists:
Dr. Stanley E. Althof, Executive Director, Center for Marital and Sexual Health of South Florida and Voluntary Professor in the Department of Psychiatry at University of Miami Miller School of Medicine. Dr. Althofis a clinician and scientist whose research focuses on the psychosocial aspects of sexual dysfunction and their impact. He has been involved in the development and validation of clinical outcome measures, research design methodologies, and clinical trials on a variety of new treatments for male and female sexual problems.
Dr. Culley C. Carson, Rhodes Distinguished Professor and Chief of Urology, University of North Carolina, School of Medicine at Chapel Hill. Dr.Carson's specialties include male sexual dysfunction. He has published more than 200 peer review publications and edited eight textbooks. He is Past President of the Sexual Medicine Society and of the Southeast Section of the American Urologic Association.
Dr. Michael P. O'Leary, Professor of Surgery, Harvard Medical School and in the Division of Urology at Brigham & Women's and Massachusetts General Hospitals, Boston. Dr. O'Leary is a pioneer in the field of male sexual disorders and has treated thousands of patients with various conditions, including erectile dysfunction, low sex drive and premature ejaculation.
Dr. Ridwan Shabsigh, Director, Division of Urology, Maimonides Medical Center and Professor of Clinical Urology, Columbia University, New York. Dr. Shabsigh's research focuses on the treatment of sexual dysfunctions. He has participated in numerous clinical trials on investigational drugsfor the treatment of erectile dysfunction, premature ejaculation and hypogonadism, and he has served as a principal investigator for efficacy and safety trials on a variety of new drugs and medical devices in patients with sexual dysfunctions.
Neal Farber, CEO of NeuroHealing, commented on the newly formed MAB: "This is an outstanding group of clinicians and researchers who collectively bring substantial experience in the men's sexual health field, in the treatment of premature ejaculation and in PE clinical trials. We are very pleased that these distinguished individuals and key opinion leaders have elected to join our Medical Advisory Board, and we look forward to working with them in the development of this promising drug candidate."
About NH02D Program for the Treatment of Premature Ejaculation
NH02D is a neurologically active, orally administered drug that is being developed for on-demand treatment of premature ejaculation. During testing of NH02D in healthy volunteers for another indication, the drug was unexpectedly reported to delay ejaculation during sexual activity. Subsequently, the effectiveness of NH02D has been demonstrated in a validated animal model of premature ejaculation in collaboration with Dr. Lesley Marson at the University of North Carolina.
Premature ejaculation is the most prevalent male sexual disorder affecting up to 30 percent of sexually active men and is even more prevalent than erectile dysfunction (a $3.8 billion market in 2008). Currently, there are no FDA-approved products available for the treatment of this disorder in the United States.
About NeuroHealing Pharmaceuticals ('http://www.NeuroHealing.com')
NeuroHealing Pharmaceuticals, Inc. is a clinical stage private company developing innovative treatments for specialty indications based on repositioning neurologically active compounds. Clinical stage programs include: NH001 (phase II), a dopaminergic agent to help post traumaticbrain injury patients to emerge from a coma, vegetative or minimally consciousness state; NH004 (phase II), an anticholinergic agent in a convenient intra-orally muco-adhesive dissolving film to help treat motorneuron disease patients who suffer from sialorrhea (drooling); and NH02D, a neurologically active compound to treat premature ejaculation.
(Top)